The upside may be limited though if other firms who are interested in a buyout / partnership opportunity decide they'd rather hold onto their cash.
All major BP’s are loaded to the gils with cash, what would make you think they would be timid about making a deal with a company who holds the IP for the next SOC for Alzheimer’s and Parkinsons?